Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling
Abstract
:Simple Summary
Abstract
1. Introduction
2. Overview of FGF/FGFR Signaling
3. Hyperactivated FGFR3 in Bladder Cancer
4. Targeting Hyperactivated FGFR3 in Advanced Bladder Cancer
4.1. Small Molecule Tyrosine Kinase Inhibitors
4.2. Neutralizing Antibodies and FGF Ligand-Traps Targeting FGFR
5. Resistance to FGFR Inhibitors in Cancer
6. FGFR Inhibitors in Combination Therapies
7. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Westergren, D.-O.; Gårdmark, T.; Lindhagen, L.; Chau, A.; Malmström, P.-U. A Nationwide, Population Based Analysis of Patients with Organ Confined, Muscle Invasive Bladder Cancer Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014. J. Urol. 2019, 202, 905–912. [Google Scholar] [CrossRef]
- Tran, L.; Xiao, J.-F.; Agarwal, N.; Duex, J.E.; Theodorescu, D. Advances in bladder cancer biology and therapy. Nat. Rev. Cancer 2020, 21, 104–121. [Google Scholar] [CrossRef]
- Grossman, H.B.; Natale, R.B.; Tangen, C.M.; Speights, V.; Vogelzang, N.J.; Trump, D.L.; White, R.W.D.; Sarosdy, M.F.; Wood, D.P.; Raghavan, D.; et al. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer. N. Engl. J. Med. 2003, 349, 859–866. [Google Scholar] [CrossRef]
- Fairey, A.S.; Daneshmand, S.; Quinn, D.; Dorff, T.; Dorin, R.; Lieskovsky, G.; Schuckman, A.; Cai, J.; Miranda, G.; Skinner, E.C. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California. Urol. Oncol. Semin. Orig. Investig. 2012, 31, 1737–1743. [Google Scholar] [CrossRef]
- Galsky, M.D.; Pal, S.K.; Chowdhury, S.; Harshman, L.C.; Crabb, S.; Wong, Y.-N.; Yu-Ning, W.; Powles, T.; Moshier, E.L.; Ladoire, S.; et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 2015, 121, 2586–2593. [Google Scholar] [CrossRef]
- Herchenhorn, D.; Dienstmann, R.; Peixoto, F.A.; De Campos, F.S.; Santos, V.O.; Moreira, D.M.; Cardoso, H.; Small, I.A.; Ferreira, C.G. Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. Int. Braz. J. Urol. 2007, 33, 630–638. [Google Scholar] [CrossRef]
- Pal, S.K.; Ruel, N.H.; Wilson, T.G.; Yuh, B.E. Retrospective Analysis of Clinical Outcomes with Neoadjuvant Cisplatin-Based Regimens for Muscle-Invasive Bladder Cancer. Clin. Genitourin. Cancer 2012, 10, 246–250. [Google Scholar] [CrossRef] [Green Version]
- Patel, V.G.; Oh, W.K.; Galsky, M.D. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA A Cancer J. Clin. 2020, 70, 404–423. [Google Scholar] [CrossRef] [PubMed]
- Robertson, A.G.; Kim, J.; Al-Ahmadie, H.; Bellmunt, J.; Guo, G.; Cherniack, A.D.; Hinoue, T.; Laird, P.W.; Hoadley, K.; Akbani, R.; et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 2017, 171, 540–556.e25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sanchez-Vega, F.; Mina, M.; Armenia, J.; Chatila, W.K.; Luna, A.; La, K.C.; Dimitriadoy, S.; Liu, D.L.; Kantheti, H.S.; Saghafinia, S.; et al. Oncogenic Signaling Pathways in the Cancer Genome Atlas. Cell 2018, 173, 321–337.e10. [Google Scholar] [CrossRef] [Green Version]
- Martínez-Jiménez, F.; Muiños, F.; Sentís, I.; Deu-Pons, J.; Reyes-Salazar, I.; Arnedo-Pac, C.; Mularoni, L.; Pich, O.; Bonet, J.; Kranas, H.; et al. A compendium of mutational cancer driver genes. Nat. Rev. Cancer 2020, 20, 65. [Google Scholar] [CrossRef]
- Iranzo, J.; Martincorena, I.; Koonin, E.V. Cancer-mutation network and the number and specificity of driver mutations. Proc. Natl. Acad. Sci. USA 2018, 115, E6010–E6019. [Google Scholar] [CrossRef] [Green Version]
- Loriot, Y.; Necchi, A.; Park, S.H.; Garcia-Donas, J.; Huddart, R.; Burgess, E.; Fleming, M.; Rezazadeh, A.; Mellado, B.; Varlamov, S.; et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N. Engl. J. Med. 2019, 381, 338–348. [Google Scholar] [CrossRef]
- Ornitz, D.M.; Itoh, N. The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 2015, 4, 215–266. [Google Scholar] [CrossRef] [Green Version]
- Turner, N.; Grose, R. Fibroblast growth factor signalling: From development to cancer. Nat. Rev. Cancer 2010, 10, 116–129. [Google Scholar] [CrossRef] [PubMed]
- Mohammadi, M.; Olsen, S.; Ibrahimi, O.A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005, 16, 107–137. [Google Scholar] [CrossRef] [PubMed]
- di Martino, E.; L’Hôte, C.G.; Kennedy, W.; Tomlinson, D.; Knowles, M. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene 2009, 28, 4306–4316. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- D’Avis, P.Y.; Robertson, S.C.; Meyer, A.N.; Bardwell, W.M.; Webster, M.K.; Donoghue, D.J. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ. Mol. Biol. J. Am. Assoc. Cancer Res. 1998, 9, 71–78. [Google Scholar]
- MacArthur, C.; Lawshe, A.; Xu, J.; Santos-Ocampo, S.; Heikinheimo, M.; Chellaiah, A.; Ornitz, D. FGF-8 isoforms activate receptor splice forms that are expressed in mesenchymal regions of mouse development. Development 1995, 121, 3603–3613. [Google Scholar] [CrossRef] [PubMed]
- Sun, X.; Mariani, F.V.; Martin, G.R. Functions of FGF signalling from the apical ectodermal ridge in limb development. Nature 2002, 418, 501–508. [Google Scholar] [CrossRef]
- Bellusci, S.; Grindley, J.; Emoto, H.; Itoh, N.; Hogan, B. Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung. Development 1997, 124, 4867–4878. [Google Scholar] [CrossRef]
- Braun, S.; Keller, U.A.D.; Steiling, H.; Werner, S. Fibroblast growth factors in epithelial repair and cytoprotection. Philos. Trans. R. Soc. B Biol. Sci. 2004, 359, 753–757. [Google Scholar] [CrossRef] [Green Version]
- Scotet, E.; Houssaint, E. The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific. Biochim. Biophys. Acta (BBA) Gene Struct. Expr. 1995, 1264, 238–242. [Google Scholar] [CrossRef]
- Murgue, B.; Tsunekawa, S.; Rosenberg, I.; Debeaumont, M.; Podolsky, D.K. Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium. Cancer Res. 1994, 54, 5206–5211. [Google Scholar] [PubMed]
- Steinberg, F.; Zhuang, L.; Beyeler, M.; Kälin, R.E.; Mullis, P.E.; Brandli, A.; Trueb, B. The FGFRL1 Receptor Is Shed from Cell Membranes, Binds Fibroblast Growth Factors (FGFs), and Antagonizes FGF Signaling in Xenopus Embryos. J. Biol. Chem. 2010, 285, 2193–2202. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Trueb, B.; Zhuang, L.; Taeschler, S.; Wiedemann, M. Characterization of FGFRL1, a Novel Fibroblast Growth Factor (FGF) Receptor Preferentially Expressed in Skeletal Tissues. J. Biol. Chem. 2003, 278, 33857–33865. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ornitz, D.M.; Xu, J.; Colvin, J.S.; McEwen, D.G.; MacArthur, C.A.; Coulier, F.; Gao, G.; Goldfarb, M. Receptor Specificity of the Fibroblast Growth Factor Family. J. Biol. Chem. 1996, 271, 15292–15297. [Google Scholar] [CrossRef] [Green Version]
- Ornitz, D.M. FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. BioEssays 2000, 22, 108–112. [Google Scholar] [CrossRef]
- Goetz, R.; Beenken, A.; Ibrahimi, O.A.; Kalinina, J.; Olsen, S.K.; Eliseenkova, A.V.; Xu, C.; Neubert, T.A.; Zhang, F.; Linhardt, R.J.; et al. Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily Members. Mol. Cell. Biol. 2007, 27, 3417–3428. [Google Scholar] [CrossRef] [Green Version]
- Zhang, X.; Ibrahimi, O.A.; Olsen, S.; Umemori, H.; Mohammadi, M.; Ornitz, D.M. Receptor Specificity of the Fibroblast Growth Factor Family. J. Biol. Chem. 2006, 281, 15694–15700. [Google Scholar] [CrossRef] [Green Version]
- Kurosu, H.; Ogawa, Y.; Miyoshi, M.; Yamamoto, M.; Nandi, A.; Rosenblatt, K.P.; Baum, M.G.; Schiavi, S.; Hu, M.-C.; Moe, O.W.; et al. Regulation of Fibroblast Growth Factor-23 Signaling by Klotho. J. Biol. Chem. 2006, 281, 6120–6123. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ogawa, Y.; Kurosu, H.; Yamamoto, M.; Nandi, A.; Rosenblatt, K.P.; Goetz, R.; Eliseenkova, A.V.; Mohammadi, M.; Kuro, M. βKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. USA 2007, 104, 7432–7437. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Urakawa, I.; Yamazaki, Y.; Shimada, T.; Iijima, K.; Hasegawa, H.; Okawa, K.; Fujita, T.; Fukumoto, S.; Yamashita, T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444, 770–774. [Google Scholar] [CrossRef] [PubMed]
- Ding, X.; Boney-Montoya, J.; Owen, B.; Bookout, A.L.; Coate, K.; Mangelsdorf, D.J.; Kliewer, S.A. βKlotho Is Required for Fibroblast Growth Factor 21 Effects on Growth and Metabolism. Cell Metab. 2012, 16, 387–393. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kharitonenkov, A.; Dunbar, J.D.; Bina, H.A.; Bright, S.; Moyers, J.S.; Zhang, C.; Ding, L.; Micanovic, R.; Mehrbod, S.F.; Knierman, M.; et al. FGF-21/FGF-21 receptor interaction and activation is determined by βKlotho. J. Cell. Physiol. 2007, 215, 1–7. [Google Scholar] [CrossRef]
- Sun, J.; Niu, C.; Ye, W.; An, N.; Chen, G.; Huang, X.; Wang, J.; Chen, X.; Shen, Y.; Huang, S.; et al. FGF13 Is a Novel Regulator of NF-κB and Potentiates Pathological Cardiac Hypertrophy. iScience 2020, 23, 101627. [Google Scholar] [CrossRef]
- Pablo, J.L.; Wang, C.; Presby, M.M.; Pitt, G.S. Polarized localization of voltage-gated Na+ channels is regulated by concerted FGF13 and FGF14 action. Proc. Natl. Acad. Sci. USA 2016, 113, E2665–E2674. [Google Scholar] [CrossRef] [Green Version]
- Pablo, J.L.; Pitt, G.S. FGF14 is a regulator of KCNQ2/3 channels. Proc. Natl. Acad. Sci. USA 2016, 114, 154–159. [Google Scholar] [CrossRef] [Green Version]
- Hsu, W.-C.; Wildburger, N.C.; Haidacher, S.J.; Nenov, M.; Folorunso, O.; Singh, A.; Chesson, B.C.; Franklin, W.F.; Cortez, I.; Sadygov, R.G.; et al. PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer’s disease. Exp. Neurol. 2017, 295, 1–17. [Google Scholar] [CrossRef]
- Wu, Q.-F.; Yang, L.; Li, S.; Wang, Q.; Yuan, X.-B.; Gao, X.; Bao, L.; Zhang, X. Fibroblast Growth Factor 13 Is a Microtubule-Stabilizing Protein Regulating Neuronal Polarization and Migration. Cell 2012, 149, 1549–1564. [Google Scholar] [CrossRef] [Green Version]
- Kurimoto, R.; Iwasawa, S.; Ebata, T.; Ishiwata, T.; Sekine, I.; Tada, Y.; Tatsumi, K.; Koide, S.; Iwama, A.; Takiguchi, Y. Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. Int. J. Oncol. 2016, 48, 1825–1836. [Google Scholar] [CrossRef] [Green Version]
- Hoadley, K.A.; Yau, C.; Hinoue, T.; Wolf, D.M.; Lazar, A.; Drill, E.; Shen, R.; Taylor, A.M.; Cherniack, A.D.; Thorsson, V.; et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 2018, 173, 291–304.e6. [Google Scholar] [CrossRef] [Green Version]
- Kim, P.H.; Cha, E.; Sfakianos, J.P.; Iyer, G.; Zabor, E.C.; Scott, S.N.; Ostrovnaya, I.; Ramirez, R.; Sun, A.; Shah, R.; et al. Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. Eur. Urol. 2014, 67, 198–201. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tomlinson, D.; Hurst, C.D.; Knowles, M.A. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007, 26, 5889–5899. [Google Scholar] [CrossRef] [Green Version]
- di Martino, E.; Tomlinson, D.C.; Williams, S.V.; Knowles, M. A place for precision medicine in bladder cancer: Targeting the FGFRs. Future Oncol. 2016, 12, 2243–2263. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, L.; Gong, Y.; Saci, A.; Szabo, P.M.; Martini, A.; Necchi, A.; Siefker-Radtke, A.; Pal, S.; Plimack, E.R.; Sfakianos, J.P.; et al. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. Eur. Urol. 2019, 76, 599–603. [Google Scholar] [CrossRef] [PubMed]
- van Rhijn, B.W.; Mertens, L.S.; Mayr, R.; Bostrom, P.J.; Real, F.X.; Zwarthoff, E.C.; Boormans, J.L.; Abas, C.; van Leenders, G.J.; Götz, S.; et al. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†. Eur. Urol. 2020, 78, 682–687. [Google Scholar] [CrossRef]
- Tomlinson, D.; Baldo, O.; Harnden, P.; A Knowles, M. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 2007, 213, 91–98. [Google Scholar] [CrossRef] [Green Version]
- Singh, D.; Chan, J.; Zoppoli, P.; Niola, F.; Sullivan, R.; Castano, A.; Liu, E.M.; Reichel, J.; Porrati, P.; Pellegatta, S.; et al. Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma. Science 2012, 337, 1231–1235. [Google Scholar] [CrossRef] [Green Version]
- Parker, B.C.; Annala, M.J.; Cogdell, D.E.; Granberg, K.J.; Sun, Y.; Ji, P.; Li, X.; Gumin, J.; Zheng, H.; Hu, L.; et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J. Clin. Investig. 2013, 123, 855–865. [Google Scholar] [CrossRef] [Green Version]
- Di Stefano, A.L.; Fucci, A.; Frattini, V.; Labussiere, M.; Mokhtari, K.; Zoppoli, P.; Marie, Y.; Bruno, A.; Boisselier, B.; Giry, M.; et al. Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma. Clin. Cancer Res. 2015, 21, 3307–3317. [Google Scholar] [CrossRef] [Green Version]
- Karkera, J.D.; Cardona, G.M.; Bell, K.; Gaffney, D.; Portale, J.C.; Santiago-Walker, A.; Moy, C.H.; King, P.; Sharp, M.; Bahleda, R.; et al. Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib. Mol. Cancer Ther. 2017, 16, 1717–1726. [Google Scholar] [CrossRef] [Green Version]
- Wu, Y.-M.; Su, F.; Kalyana-Sundaram, S.; Khazanov, N.; Ateeq, B.; Cao, X.; Lonigro, R.J.; Vats, P.; Wang, R.; Lin, S.-F.; et al. Identification of Targetable FGFR Gene Fusions in Diverse Cancers. Cancer Discov. 2013, 3, 636–647. [Google Scholar] [CrossRef] [Green Version]
- Guagnano, V.; Furet, P.; Spanka, C.; Bordas, V.; Le Douget, M.; Stamm, C.; Brueggen, J.; Jensen, M.R.; Schnell, C.; Schmid, H.; et al. Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase. J. Med. Chem. 2011, 54, 7066–7083. [Google Scholar] [CrossRef]
- Perera, T.P.; Jovcheva, E.; Mevellec, L.; Vialard, J.; De Lange, D.; Verhulst, T.; Paulussen, C.; Van De Ven, K.; King, P.; Freyne, E.; et al. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor. Mol. Cancer Ther. 2017, 16, 1010–1020. [Google Scholar] [CrossRef] [Green Version]
- Tabernero, J.; Bahleda, R.; Dienstmann, R.; Infante, J.R.; Mita, A.; Italiano, A.; Calvo, E.; Moreno, V.; Adamo, B.; Gazzah, A.; et al. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced Solid Tumors. J. Clin. Oncol. 2015, 33, 3401–3408. [Google Scholar] [CrossRef]
- Sequist, L.V.; Cassier, P.; Varga, A.; Tabernero, J.; Schellens, J.H.; Delord, J.-P.; Lorusso, P.; Camidge, D.R.; Medina, M.H.; Schuler, M.; et al. Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res. 2014, 74, CT326. [Google Scholar] [CrossRef]
- Pal, S.K.; Rosenberg, J.E.; Hoffman-Censits, J.H.; Berger, R.; Quinn, D.I.; Galsky, M.D.; Wolf, J.; Dittrich, C.; Keam, B.; Delord, J.-P.; et al. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. Cancer Discov. 2018, 8, 812–821. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Javle, M.M.; Roychowdhury, S.; Kelley, R.K.; Sadeghi, S.; Macarulla, T.; Waldschmidt, D.T.; Goyal, L.; Borbath, I.; El-Khoueiry, A.B.; Yong, W.-P.; et al. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. J. Clin. Oncol. 2021, 39, 265. [Google Scholar] [CrossRef]
- Gavine, P.R.; Mooney, L.; Kilgour, E.; Thomas, A.P.; Al-Kadhimi, K.; Beck, S.; Rooney, C.; Coleman, T.; Baker, D.; Mellor, M.J.; et al. AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family. Cancer Res. 2012, 72, 2045–2056. [Google Scholar] [CrossRef] [Green Version]
- Chae, Y.K.; Hong, F.; Vaklavas, C.; Cheng, H.H.; Hammerman, P.; Mitchell, E.P.; Zwiebel, J.A.; Ivy, S.P.; Gray, R.J.; Li, S.; et al. Phase II Study of AZD4547 in Patients with Tumors Harboring Aberrations in the FGFR Pathway: Results from the NCI-MATCH Trial (EAY131) Subprotocol W. J. Clin. Oncol. 2020, 38, 2407–2417. [Google Scholar] [CrossRef] [PubMed]
- Collin, M.-P.; Lobell, M.; Hübsch, W.; Brohm, D.; Schirok, H.; Jautelat, R.; Lustig, K.; Bömer, U.; Vöhringer, V.; Héroult, M.; et al. Discovery of Rogaratinib (BAY 1163877): A pan-FGFR Inhibitor. ChemMedChem 2018, 13, 437–445. [Google Scholar] [CrossRef] [PubMed]
- Grünewald, S.; Politz, O.; Bender, S.; Héroult, M.; Lustig, K.; Thuss, U.; Kneip, C.; Kopitz, C.; Zopf, D.; Collin, M.; et al. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Int. J. Cancer 2019, 145, 1346–1357. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schuler, M.; Cho, B.C.; Sayehli, C.M.; Navarro, A.; Soo, R.; Richly, H.; Cassier, P.A.; Tai, D.; Penel, N.; Nogova, L.; et al. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: A phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019, 20, 1454–1466. [Google Scholar] [CrossRef]
- Quinn, D.I.; Petrylak, D.P.; Bellmunt, J.; Necchi, A.; Gurney, H.; Lee, J.-L.; Van Der Heijden, M.S.; Rosenbaum, E.; Penel, N.; Pang, S.-T.; et al. FORT-1: Phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression. J. Clin. Oncol. 2020, 38, 489. [Google Scholar] [CrossRef]
- Liu, P.C.C.; Koblish, H.; Wu, L.; Bowman, K.; Diamond, S.; DiMatteo, D.; Zhang, Y.; Hansbury, M.; Rupar, M.; Wen, X.; et al. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLoS ONE 2020, 15, e0231877. [Google Scholar] [CrossRef]
- Abou-Alfa, G.K.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A.S.; Borad, M.J.; Gallinson, D.; Murphy, A.G.; et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol. 2020, 21, 671–684. [Google Scholar] [CrossRef]
- Martinez-Torrecuadrada, J.L.; Cifuentes, G.; Lopez-Serra, P.; Saenz, P.; Martínez, A.; Casal, J.I. Targeting the Extracellular Domain of Fibroblast Growth Factor Receptor 3 with Human Single-Chain Fv Antibodies Inhibits Bladder Carcinoma Cell Line Proliferation. Clin. Cancer Res. 2005, 11, 6280–6290. [Google Scholar] [CrossRef] [Green Version]
- Necchi, A.; Castellano, D.E.; Mellado, B.; Pang, S.; Urun, Y.; Park, S.H.; Vaishampayan, U.N.; Currie, G.; Abella-Dominicis, E.; Pal, S.K. Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC). J. Clin. Oncol. 2019, 37, 409. [Google Scholar] [CrossRef]
- Siefker-Radtke, A.O.; Currie, G.; Abella, E.; Vaena, D.A.; Kalebasty, A.R.; Curigliano, G.; Tupikowski, K.; Andric, Z.G.; Lugowska, I.; Kelly, W.K. FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. J. Clin. Oncol. 2019, 37, 4511. [Google Scholar] [CrossRef]
- Qing, J.; Du, X.; Chen, Y.; Chan, P.; Li, H.; Wu, P.; Marsters, S.; Stawicki, S.; Tien, J.; Totpal, K.; et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J. Clin. Investig. 2009, 119, 1216–1229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yin, Y.; Djakovic, S.; Marsters, S.; Tien, J.; Peng, J.; Tremayne, J.; Lee, G.; Neve, R.M.; Wu, Y.; Merchant, M.; et al. Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity. Mol. Cancer Ther. 2015, 14, 2270–2278. [Google Scholar] [CrossRef] [Green Version]
- Tolcher, A.W.; Papadopoulos, K.P.; Patnaik, A.; Wilson, K.; Thayer, S.; Zanghi, J.; Gemo, A.T.; Kavanaugh, W.M.; Keer, H.N.; LoRusso, P.M. A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Ann. Oncol. 2015, 27, 526–532. [Google Scholar] [CrossRef]
- Garcia, S.; Dirat, B.; Tognacci, T.; Rochet, N.; Mouska, X.; Bonnafous, S.; Patouraux, S.; Tran, A.; Gual, P.; Le Marchand-Brustel, Y.; et al. Postnatal Soluble FGFR3 Therapy Rescues Achondroplasia Symptoms and Restores Bone Growth in Mice. Sci. Transl. Med. 2013, 5, 203ra124. [Google Scholar] [CrossRef]
- Schram, A.M.; Chang, M.T.; Jonsson, P.; Drilon, A. Fusions in solid tumours: Diagnostic strategies, targeted therapy, and acquired resistance. Nat. Rev. Clin. Oncol. 2017, 14, 735–748. [Google Scholar] [CrossRef]
- Camidge, D.R.; Pao, W.; Sequist, L.V. Acquired resistance to TKIs in solid tumours: Learning from lung cancer. Nat. Rev. Clin. Oncol. 2014, 11, 473–481. [Google Scholar] [CrossRef]
- Cowell, J.K.; Qin, H.; Hu, T.; Wu, Q.; Bhole, A.; Ren, M. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas. Int. J. Cancer 2017, 141, 1822–1829. [Google Scholar] [CrossRef] [Green Version]
- Jiang, K.; Tang, X.; Guo, J.; He, R.; Chan, S.; Song, X.; Tu, Z.; Wang, Y.; Ren, X.; Ding, K.; et al. GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo. Cancer Med. 2021, 10, 4874–4884. [Google Scholar] [CrossRef]
- Chell, V.; Balmanno, K.; Little, A.S.; Wilson, M.L.; Andrews, S.; Blockley, L.Y.; Hampson, M.; Gavine, P.R.; Cook, S. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene 2012, 32, 3059–3070. [Google Scholar] [CrossRef] [Green Version]
- Wang, L.; Šuštić, T.; de Oliveira, R.L.; Lieftink, C.; Halonen, P.; van de Ven, M.; Beijersbergen, R.; Heuvel, M.M.V.D.; Bernards, R.; van der Heijden, M.S. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. Eur. Urol. 2017, 71, 858–862. [Google Scholar] [CrossRef]
- Ware, K.E.; Marshall, M.E.; Heasley, L.R.; Marek, L.; Hinz, T.K.; Hercule, P.; Helfrich, B.A.; Doebele, R.C.; Heasley, L.E. Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression. PLoS ONE 2010, 5, e14117. [Google Scholar] [CrossRef]
- Day, E.K.; Sosale, N.G.; Xiao, A.; Zhong, Q.; Purow, B.; Lazzara, M.J. Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling. Cell Rep. 2020, 30, 3383–3396.e7. [Google Scholar] [CrossRef] [Green Version]
- Bernat-Peguera, A.; Navarro-Ventura, J.; Lorenzo-Sanz, L.; da Silva-Diz, V.; Bosio, M.; Palomero, L.; Penin, R.M.; Sidelnikova, D.P.; Bermejo, J.O.; Taberna, M.; et al. FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma. Clin. Cancer Res. 2020, 27, 1491–1504. [Google Scholar] [CrossRef]
- Raoof, S.; Mulford, I.J.; Frisco-Cabanos, H.; Nangia, V.; Timonina, D.; Labrot, E.; Hafeez, N.; Bilton, S.J.; Drier, Y.; Ji, F.; et al. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene 2019, 38, 6399–6413. [Google Scholar] [CrossRef]
- Hanker, A.; Garrett, J.J.; Estrada, M.V.; Moore, P.P.; Ericsson, P.G.; Koch, J.J.; Langley, E.E.; Singh, S.S.; Kim, P.P.; Frampton, G.G.; et al. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin. Cancer Res. 2017, 23, 4323–4334. [Google Scholar] [CrossRef] [Green Version]
- Malchers, F.; Ercanoglu, M.; Schuette, D.; Castiglione, R.; Tischler, V.; Michels, S.; Dahmen, I.; Brägelmann, J.; Menon, R.; Heuckmann, J.M.; et al. Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer. Clin. Cancer Res. 2017, 23, 5527–5536. [Google Scholar] [CrossRef] [Green Version]
- Manchado, E.; Weissmueller, S.; Morris, J.P.; Chen, C.-C.; Wullenkord, R.; Lujambio, A.; De Stanchina, E.; Poirier, J.; Gainor, J.F.; Corcoran, R.B.; et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 2016, 534, 647–651. [Google Scholar] [CrossRef] [Green Version]
- Lee, H.-J.; Zhuang, G.; Cao, Y.; Du, P.; Kim, H.-J.; Settleman, J. Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells. Cancer Cell 2014, 26, 207–221. [Google Scholar] [CrossRef] [Green Version]
- Bellmunt, J.; De Wit, R.; Vaughn, D.J.; Fradet, Y.; Lee, J.-L.; Fong, L.; Vogelzang, N.J.; Climent, M.A.; Petrylak, D.P.; Choueiri, T.K.; et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N. Engl. J. Med. 2017, 376, 1015–1026. [Google Scholar] [CrossRef] [Green Version]
- Rosenberg, J.; Hoffman-Censits, J.; Powles, T.; van der Heijden, M.S.; Balar, A.; Necchi, A.; Dawson, N.; O’Donnell, P.H.; Balmanoukian, A.; Loriot, Y.; et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 2016, 387, 1909–1920. [Google Scholar] [CrossRef] [Green Version]
- Foth, M.; Ismail, N.F.B.; Kung, J.S.C.; Tomlinson, D.; Knowles, M.A.; Eriksson, P.; Sjödahl, G.; Salmond, J.M.; Sansom, O.J.; Iwata, T. FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation. J. Pathol. 2018, 246, 331–343. [Google Scholar] [CrossRef] [Green Version]
- Palakurthi, S.; Kuraguchi, M.; Zacharek, S.J.; Zudaire, E.; Huang, W.; Bonal, D.M.; Liu, J.; Dhaneshwar, A.; Depeaux, K.; Gowaski, M.R.; et al. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity. Cancer Immunol. Res. 2019, 7, 1457–1471. [Google Scholar] [CrossRef] [Green Version]
- Akhand, S.S.; Liu, Z.; Purdy, S.C.; Abdullah, A.; Lin, H.; Cresswell, G.M.; Ratliff, T.L.; Wendt, M.K. Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade. Cancer Immunol. Res. 2020, 8, 1542–1553. [Google Scholar] [CrossRef]
- Powles, T.; Carroll, D.; Chowdhury, S.; Gravis, G.; Joly, F.; Carles, J.; Fléchon, A.; Maroto, P.; Petrylak, D.; Rolland, F.; et al. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nat. Med. 2021, 27, 793–801. [Google Scholar] [CrossRef]
Compounds | Clinical Trial | Clinical Trial ID | Phase | Sponsor |
---|---|---|---|---|
Erdafitinib, Midazolam, Metformin | An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants with Urothelial Cancer | NCT02365597 | II | Janssen Research & Development, LLC (Raritan, NJ, USA) |
Derazantinib and Atezolizumab | Derazantinib and Atezolizumab in Patients with Urothelial Cancer (FIDES-02) | NCT04045613 | I & II | Basilea Pharmaceutica (Basel, Switzerland) |
Futibatinib and Pembrolizumab Combination | Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma | NCT04601857 | II | Taiho Oncology, Inc. (Tokyo, Japan) |
Rogaratinib (BAY1163877) in Combination with Atezolizumab | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination with Atezolizumab in Urothelial Carcinoma (FORT-2) | NCT03473756 | Ib/II | Bayer (Leverkusen, Germany) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Xiao, J.-F.; Caliri, A.W.; Duex, J.E.; Theodorescu, D. Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling. Cancers 2021, 13, 4891. https://doi.org/10.3390/cancers13194891
Xiao J-F, Caliri AW, Duex JE, Theodorescu D. Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling. Cancers. 2021; 13(19):4891. https://doi.org/10.3390/cancers13194891
Chicago/Turabian StyleXiao, Jin-Fen, Andrew W. Caliri, Jason E. Duex, and Dan Theodorescu. 2021. "Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling" Cancers 13, no. 19: 4891. https://doi.org/10.3390/cancers13194891